Daiichi-Sankyo (Japan)
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Daiichi-Sankyo (Japan), Japan, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
46%
Total
Publications
5.5K
Total Open
Publications
2.5K
Total
Citations
181K
Open Access
Percentage
46%
Total
Publications
5.5K
Total Open
Publications
2.5K
Total
Citations
181K
Breakdown
Publisher Open
23%
Both
18%
Other Platform Open
4%
Closed
55%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 32%
710
Hybrid 25%
565
No Guarantees 43%
977
Other Platform Open
Domain 75%
945
Other Internet 21%
261
Institution 15%
192
Preprint 3%
42
Public 3%
41
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 943 |
DOI | Other Internet | 259 |
Europe PMC | Domain | 62 |
Royal Netherlands Academy of Arts and Sciences | Institution | 61 |
Figshare | Public | 39 |
King's College London | Institution | 19 |
bioRxiv | Preprint | 19 |
Research Square | Preprint | 17 |
universiteitleiden.nl OAI-PMH Repository | Institution | 13 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 11 |